Navigation Links
Long-Term Outcomes for Prostate Cancer Show IMRT Curative

Results from the largest study of men with prostate cancer treated with high-dose, intensity modulated radiation therapy (IMRT) show that the majority // of patients remain alive with no evidence of disease after an average follow-up period of eight years.

The 561 prostate cancer patients treated with IMRT at Memorial Sloan-Kettering Cancer Center were classified into prognostic risk groups. After an average of eight years, 89 percent of the men in the favorable risk group were disease-free and none of the men in any group developed secondary cancers as a result of the radiation therapy. This report, published in the October 2006 issue of The Journal of Urology, is the first description of long-term outcomes for prostate cancer patients using IMRT.

"Our results suggest that IMRT should be the treatment of choice for delivering high-dose, external beam radiotherapy for patients with localized prostate cancer," said Dr. Michael J. Zelefsky, Chief of the Brachytherapy Service at Memorial Sloan-Kettering. "We were able to show long-term safety and long-term efficacy in a very diverse group of prostate cancer patients that we followed – many for as long as ten years. Despite the fact that some patients had an aggressive form of their disease with high Gleason scores and PSA (prostate specific antigen) levels, the overwhelming majority of patients had good tumor control with neither recurrence of their original cancer nor development of second cancers, which one might have expected from the high doses of radiation," he added.

Pre-treatment diagnostic evaluations were performed for all of the patients to better define their clinically localized prostate cancer. They were classified into prognostic risk groups as defined by the National Comprehensive Cancer Network guidelines (http://www.nccn.org). These are based on clinical characteristics including age, T stage, Gleason score, PSA level, and pre-treatment with neoadjuvant androgen depr ivation.

Between April 1996 and January 2000, 561 patients with a median age of 68 (ranging from 46 to 86 years old) were treated with IMRT, an improved form of three-dimensional conformal radiation therapy (3D-CRT), also used in radiotherapy. IMRT uses enhanced planning treatment software that more precisely targets the prostate, allowing the beam of radiation to deliver a high dose (81 Gy) to the tumor target while sparing the adjacent bladder and rectum from exposure to the higher amounts of radiation. Perhaps because of this, the eight-year results show urinary continence was maintained for all patients, and only 1.6 percent of the five hundred sixty-one patients experienced rectal bleeding. The high-dose radiotherapy was curative for the majority of the patients in all three prognostic risk groups, with 89 percent of the favorable, 78 percent of the intermediate, and 67 percent of the unfavorable group alive after an average period of eight years. Of those men who were potent prior to IMRT, erectile dysfunction developed in 49 percent.

“This study confirms that we can improve patients’ quality of life by reducing the side effects of radiotherapy while maintaining disease-free survival,” said Dr. Zelefsky. “However, there is still room for improvement. We are incorporating image-guided approaches that may continue the excellent tumor control but further limit the area we are irradiating and reduce side-effects."

Source-Newswise'"/>




Related medicine news :

1. Pancreatitis: Minimially Invasive Procedure Offers Long-Term Pain Relief
2. Long-Term Survival can be Predicted by a Simple Lung Test
3. Lung Therapy Found To Have Long-Term Side Effects
4. Long-Term Benefits Of Statins Questioned
5. Clue to Link Between Obesity and Long-Term Memory Discovered
6. Drug Regulators Need To Think In Long-Term, Say Charities
7. Aspirin and other NSAIDS Proved Less Effective in Long-Term Smokers
8. Pharmacists to take over Treatment of Long-Term Illnesses
9. Kyphoplasty Yields Good Long-Term Improvement for Spinal Fractures
10. Hemorrhoid Stapling Has More Long-Term Risks Than Surgical Removal
11. IMRT Versus 3D CRT For Prostate Cancer, New Long-Term Data Assesses Side Effects
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/24/2016)... ... 2016 , ... Those who have experienced traumatic events may suffer from a ... such as drug or alcohol abuse, as a coping mechanism. To avoid this pain ... following a traumatic event. , Trauma sufferers tend to feel a range of emotions, ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... Marcy was in a crisis. Her son ... lash out at his family verbally and physically. , “When something upset him, he couldn’t ... would use it. He would throw rocks at my other children and say he was ...
(Date:6/24/2016)... MIAMI, Fla. (PRWEB) , ... June 24, 2016 , ... ... Florida Trend magazine’s 2016 Legal Elite. The attorneys chosen by their peers for this ... of Florida. , Seven Greenberg Traurig Shareholders received special honors as members of this ...
(Date:6/24/2016)... ... 2016 , ... Comfort Keepers® of San Diego, CA is excited to announce ... program to drive cancer patients to and from their cancer treatments. Comfort Keepers ... of life and ongoing independence. Getting to and from medical treatments is one ...
(Date:6/24/2016)... ... June 24, 2016 , ... People across the U.S. are sharpening their ... Award, an essay contest in which patients and their families pay tribute to a ... the 2016 National Society of Genetic Counselors (NSGC) Annual Education Conference (AEC) this September. ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... 2016 Research and Markets ... Electronics 2015-2025: Applications, Technologies, Forecasts" report to ... In-Mold Electronics, Smart Skin, Structural Health Monitoring, Composite ... Structural electronics involves electronic and/or electrical components and ... dumb structures such as vehicle bodies or conformally ...
(Date:6/24/2016)... 2016 Research and Markets has announced ... Diagnostic Tests" report to their offering. ... The World Market for Companion Diagnostics covers ... Market analysis in the report includes the following: ... Diagnostic Kits) by Region (N. America, EU, ROW), 2015-2020 ...
(Date:6/24/2016)... , June 24, 2016  Arkis BioSciences, ... less invasive and more durable cerebrospinal fluid treatments, ... funding.  The Series-A funding is led by Innova ... Fund, and other private investors.  Arkis, new financing ... instrumentation and the market release of its in-licensed ...
Breaking Medicine Technology: